

PainWeek[®]

Ain't No Honky Tonk: Medical Cannabis for Pain Management

Theresa Mallick-Searle, MS, PMGT-BC, ANP

Title & Affiliation

Theresa Mallick-Searle, MS, NP-BC, ANP-BC

Nurse Practitioner, Pain Medicine

Stanford Health Care

Division of Pain Medicine

Stanford, CA

Disclosure

- Speakers Bureau: Salix, AbbVie (Allergan), Lilly
- Any unlabeled/unapproved uses of drugs or products referenced will be disclosed.
- Covering a very LARGE topic in a short amount of time.

Learning Objectives

Cite

Cite potential drug interactions with cannabis



Describe

Describe safety considerations for both patients and clinicians



Summarize


Summarize how to negotiate the dispensary

Speaker's Expectations

- You have heard about cannabis.
- You know a little about the differences between THC & CBD.
- You have a vague grasp of the endocannabinoid system.
- Your patient wants to try/has questions about/likes to joke about/is using cannabis.
- You are “a busy clinician and have 15 (maybe 20) minutes to learn all that I need to know about cannabis.”

Where Does the Country Stand – as of June 2021

<https://www.mpp.org/states/>



Agriculture Improvement Act/Hemp Farming Act 2018

- Removed hemp for the U.S. list of scheduled substances.
- Did not remove hemp derived cannabinoids from the list of scheduled I substances.
- Amended the definition of marijuana → included an exemption for hemp → defined as “any part” of the *Cannabis sativa* L. plant → containing no more than 0.3% THC.
- Ongoing legislation → federal & regulatory agency guidance.
- States setting their own rules for the hemp industry.
- USDA has broad regulatory “authority” over hemp industry.

Cannabis Administration & Opportunity Act 2021

- Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR) & Sen. Cory Booker (D-NJ)
 - federally deschedule cannabis
 - expunge prior convictions
 - maintain the authority of states to set their own marijuana policies
 - impose a federal tax on marijuana products
 - social equity components
- The Marijuana Opportunity, Reinvestment & Expungement (MORE) Act passed the House but did not advance in the Senate under GOP control.
- Separately, a proposal to federally deschedule marijuana that does not include social equity components was recently filed by a pair of Republican congressmen.

Endocannabinoid System: Endogenous-Homeostatic regulatory system-Inherited by all mammals


HUMAN ENDOCANNABINOID SYSTEM

THE MOST WELL KNOWN CANNABINOID RECEPTORS, CB1 AND CB2, ARE PROTEINS THAT ARE IMBEDDED IN THE MEMBRANE OF CELLS. THESE SURFACE PROTEINS ARE THEN ATTACHED TO ANOTHER PROTEIN THAT DETERMINES THE SIGNALING DIRECTION ACTIVATION OR INHIBITION

CB1

CB1 Receptors target :

- Appetite
- Immune cells
- Motor activity
- Motor coordination
- Pain perception
- Short term memory
- Thinking



CB2

CB2 Receptors target :

- Adipose tissue
- Bone
- Cardiovascular system
- Central nervous system
- Eyes
- Gut
- Immune system
- Kidneys
- Liver
- Pancreas
- Reproductive system
- Respiratory tract
- Skeletal muscle
- Skin
- Tumors

CB1

CB1 Receptors are primarily found in the brain and central nervous system, and to a lesser extent in the other tissues.

CB2

CB2 Receptors are mostly in the peripheral organs especially cells associated with the immune system.

Clinical Endocannabinoid Deficiency

Ethan Russo, MD (2004/2016)



- The eCS theory of disease.
- Lack of sufficient endocannabinoids/dysregulation of the eCS.
- Result in higher susceptibility (fibromyalgia, irritable bowel syndrome, depression, anxiety, migraine).
- Phytocannabinoids (THC, CBD) can bind to the cannabinoid receptor sites (CB1, CB2), and mimic the physiological processes seen with binding of the endocannabinoids.



Genetic & Epigenetic Influences on eCS

- Seizures, nerve pain, sleep deprivation - ↑ CB1R in brain (Karlocai et al, 2011; Navarro et al, 2003; Siegling et al, 2001).
- Crohn's – ↑ CB1R in intestines (Izzo et al, 2001).
- Autistic children - ↑CB2R on white blood cells (Siniscalco et al, 2013).
- Depression/suicidality - ↑ CB1R (Hungund et al, 2004).
- Studies have looked at association between ADHD and a specific polymorphism of the cannabinoid CB1 receptor gene. (Lu et al, 2008).

A large-scale genome-wide association study meta-analysis of cannabis use disorder


[Emma C Johnson, PhD](#)  *  • [Ditte Demontis, PhD](#) * • [Thorgeir E Thorgeirsson, PhD](#) * • [Raymond K Walters, PhD](#) • [Renato Polimanti, PhD](#) • [Alexander S Hatoum, PhD](#) • et al. [Show all authors](#) • [Show footnotes](#)

[Open Access](#) • Published: October 20, 2020 • DOI: [https://doi.org/10.1016/S2215-0366\(20\)30339-4](https://doi.org/10.1016/S2215-0366(20)30339-4) •

- A small fraction of cannabis users develop cannabis use disorder.
- A 2016 study conducted by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, found that 2.5% percent of American adults—nearly 6 million people—experienced cannabis use disorder in the 12 months prior to the study, while 6.3% had met the diagnostic criteria for the disorder at some point in their lives.
- The new genome-wide association study (GWAS), a “meta-analysis” of 20 existing population samples - analyzed genome data of 20,196 individuals with cannabis use disorder and 363,116 controls.
 - cannabis use disorder is positively correlated, at the level of genetic variation, with other psychiatric disorders, including ADHD, major depression, & schizophrenia.

Entourage Effect: Sum of the Parts

- The entourage effect is a proposed mechanism by which cannabis compounds act synergistically to modulate the overall physiological effects of the plant.
- Example: CBD + THC = possibly mitigating some of the psychosis-like effects of THC.
- Cannabis is a multimodal treatment. It can be used to treat multiple symptoms & conditions concurrently, which can therefore help to reduce polypharmacy burden.



What is Cannabis Sativa (aka marijuana)?

It is a Plant w/over 400 different chemicals:

- >60 types of cannabinoids
 - delta-9-tetrahydrocannabinol (THC)
 - Cannabidiol (CBD)
 - Cannabinol (CBN)
 - Cannabichromene (CBC)
 - Cannabigerol (CBG)
 - Tetrahydrocannabivarin (THCV)
- Flavonoids, Terpenes, Terpenoids
- Fungus? Bacteria? Pesticides?
- Byproducts of manufacturing (solvents, heavy metals)



Current Reviews/Meta-analysis



Cochrane Database of Systematic Reviews

Cannabis-based medicines for chronic neuropathic pain in adults (Review)

2018

Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W

■ META-ANALYSIS


Anesth Analg 2017;125:1638-52

Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis

Howard Meng, MD,* Bradley Johnston, PhD,†‡§|| Marina Englesakis, MLIS,¶|| Dwight E. Moulin, MD,# and Anuj Bhatia, MBBS, MD, FRCPC, FRCA, FFPMRCA, FIPP, EDRA, CIPS*

JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358

The National Academies of
SCIENCES • ENGINEERING • MEDICINE



Original Investigation

Cannabinoids for Medical Use A Systematic Review and Meta-analysis

Penny F. Whiting, PhD; Robert F. Wolff, MD; Sohan Deshpande, MSc; Marcello Di Nisio, PhD; Steven Duffy, PgD; Adrian V. Hernandez, MD, PhD; J. Christiaan Keurentjes, MD, PhD; Shona Lang, PhD; Kate Misso, MSc; Steve Ryder, MSc; Simone Schmidtkofer, MSc; Marie Westwood, PhD; Jos Kleijnen, MD, PhD

Can I Get My Patient Into a Clinical Trial?

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Explore 367,204 research studies in all 50 states and in 219 countries.

See [listed clinical studies](#) related to the coronavirus disease (COVID-19)

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

Find a study (all fields optional)

Status ⓘ

Recruiting and not yet recruiting studies All studies

Condition or disease ⓘ (For example: breast cancer)

X



**Tell me EVERYTHING I need to know in
≈20 minutes!**

Important Talking Points

- Encourage open/non-judgmental dialogue.
- Driving “under the influence”.
- Recommend obtaining medical marijuana card
- Traveling considerations.
- Provide website resources.
- Share the extend of the research that is known .
- Discuss drug to plant interactions, side effects, addiction.
- Know what to look for in products.
- How to recognize who is behind the counter dispensary.



in the

Is Medical Cannabis Safe for My Patients?

European Journal of Internal Medicine 89 (2021) 10–18

Contents lists available at ScienceDirect

ELSEVIER


European Journal of Internal Medicine

journal homepage: www.elsevier.com/locate/ejim

Review Article

“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations

Caroline A. MacCallum^{a,b,c,*}, Lindsay A. Lo^d, Michael Boivin^e



Is Medical Cannabis Safe for My Patients?

Table 1. Precautions and Contraindications.

Considerations ^A	Precautions ^B	Relative Contraindications ^C	Contraindications ^{D*}
Immunocompromised	Concurrent mood or anxiety disorder	Under 25 years of age	Unstable
Chronic Kidney Disease	Have risk factors for cardiovascular disease	Current or past cannabis use disorder	cardiovascular disease
Older adults	Tobacco use	Current or past substance use disorder	Respiratory disease (if smoking cannabis)
Patients with concurrent medical conditions	E-cigarette use		Personal or strong family history of psychosis/ bipolar
Polypharmacy	Severe liver dysfunction /disease		Pregnant, planning on becoming pregnant, or breastfeeding
Potential drug interactions	Medications associated with sedation or cognitive impairment		
	Driving or safety sensitive occupations		

Interstate transportation of these products is federally illegal.

Traveling

- TSA security does not search for marijuana or other illegal drugs, but if any illegal substance is discovered during security screening, TSA will refer the matter to a law enforcement officer.
- Marijuana is illegal under federal law, & federal law governs airplane travel in this country.
- Recently, the TSA updated its rules for flying with medical marijuana, allowing travelers to now carry products like Cannabidiol (CBD) oil that contain < 0.3% THC. Passengers can bring products that are approved by the FDA in their checked or carry-on luggage.



Amtrak “The use or transportation of marijuana in any form for any purpose is prohibited, even in states or countries where recreational use is legal or permitted medically.”

Greyhound bans alcohol/drugs “anywhere on the bus (including in your checked baggage).”

Driving under the influence/Driving impaired

- Decreases reaction time.
- Feelings of drowsiness or inattention.
- Poor coordination affecting the mechanics of driving (steering, working, braking, etc.).
- Alters rational decision making.
- Alters the ability to judge car's position on the road, road signs, location of other vehicles/object/pedestrians.

- ANYTHING THAT A POLICE OFFICER DEEMS APPROPRIATE!

Tip: If documenting the discussion of cannabis use either recreationally or medicinally with a patient

DOCUMENT the advisement of risks with automobile usage.



Drug Testing for Cannabis

Many factors:

- Route of administration (inhaled, oral, topical)
 - Duration of use (acute v/s chronic usage)
 - Blood, sweat, tears (hair, saliva)
 - Sensitivity of the test (immunoassay – screening; v/s GC-MS – confirmatory)
 - Genetics – CYP450 variations, adipose tissue
- In general, the detection time is longest in hair → urine, sweat, oral fluid & blood.
- The average limit or cut-off level for testing positive on a drug test for marijuana (THC) is 50 ng/ml (15 ng/ml for GC-MS).



Drug Testing for Cannabis

Cannabinoid Test Results

12/01/2018

Cannabinoid analysis utilizing High Performance Liquid Chromatography (HPLC, QSP 5-4-4-4)

	mg/g	%	LOD mg/g	LOQ mg/g
THC	ND	ND	0.000034	0.001
THCa	ND	ND	0.000066	0.001
CBD	10.797	1.0797	0.000057	0.001
CBDa	ND	ND	0.000038	0.001
CBN	ND	ND	0.000029	0.001
CBDV	0.049	0.0049	0.000065	0.001
CBDVa	ND	ND	0.00003	0.001
CBG	ND	ND	0.000086	0.001
CBGa	ND	ND	0.000072	0.001
THCV	ND	ND	0.000035	0.001
$\Delta 8$ - THC	ND	ND	0.000083	0.001
CBC	ND	ND	0.000095	0.001
Sum of Cannabinoids:	10.846	1.0846		845.988 mg/Unit
Total THC ($\Delta 9$ THC+0.877*THCa)	ND	ND		ND
Total CBD (CBD+0.877*CBDa)	10.797	1.0797		842.166 mg/Unit

Stirring the Pot: Potential Drug Interactions

- CYP450 → Main metabolic pathway for cannabinoids
- Studies of THC, CBD & CBN inhibition and induction of major human CYP-450 isoforms generally reflect a low risk of clinically significant drug interactions with most use, but specific human data are lacking. (Stout & Cimino, 2014)
- CNS depressants, antidepressants, central nervous system drugs – potentiate effects of THC.
- Any medications that are metabolized through the same pathways could result in less or more of the drug's effects.
- For scientific reviews: Drug Metabolism Reviews.
- Epocrates is a good quick reference for cannabidiol and synthetic THC.



Review Article

“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations

Caroline A. MacCallum^{a,b,c,*}, Lindsay A. Lo^d, Michael Boivin^e

Enzyme	Interaction and effect	Drugs
CYP 3A4	<p>Inducers: may decrease THC and/or CBD</p> <p>Inhibitors: may increase THC and/or CBD</p> <p>Substrates: CBD is potential inhibitor of CYP3A4 and could increase 3A4 substrates. Caution with medications with smaller therapeutic index (e.g. tacrolimus). Unlikely to have effect on THC</p>	<p>Carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort</p> <p>Azole antifungals, clarithromycin, diltiazem, erythromycin, grapefruit, HIV protease inhibitors, macrolides, mifepristone, verapamil</p> <p>Alprazolam, atorvastatin, carbamazepine, clobazam, cyclosporine, diltiazem, HIV protease inhibitors, buprenorphine, tacrolimus, cyclosporine, phenytoin, sildenafil, simvastatin, sirolimus, verapamil, zopiclone</p>
CYP 1A1 and 1A2	<p>Substrates: Smoking cannabis can stimulate these isoenzymes and increase the metabolism of these medications.</p>	<p>Amitriptyline, caffeine, clozapine, duloxetine, estrogens, fluvoxamine, imipramine, melatonin, mirtazapine, olanzapine, theophylline</p>
p-glycoprotein	<p>Substrates: CBD may inhibit p-glycoprotein drug transport. Should monitor for toxicity. No effect from use of THC</p>	<p>Dabigatran, digoxin, loperamide</p>

CYP 2C9	<p>Inducers: may decrease THC concentration. Unlikely to have effect on CBD</p> <p>Inhibitors: may increase THC concentration. Unlikely to have effect on CBD</p> <p>Substrates: THC and/or CBD may increase drug levels, should monitor for toxicity</p>	<p>Amiodarone, fluconazole, fluoxetine, metronidazole, valproic acid, sulfamethoxazole</p> <p>Carbamazepine, rifampin</p> <p>Warfarin, rosuvastatin, phenytoin</p>
CYP 2C19	<p>Inducers: may decrease CBD and THC</p> <p>Inhibitors: may increase CBD and THC</p> <p>Substrates: CBD may increase the level of medications metabolized by 2C19 such as norclobazam (active metabolite in clobazam). CBD may also prevent clopidogrel from being activated. Unlikely to have effect on THC</p>	<p>Carbamazepine, rifampin, St. John's wort</p> <p>cimetidine, omeprazole, esomeprazole, ticlopidine, fluconazole, fluoxetine, isoniazid</p> <p>aripiprazole, citalopram, clopidogrel, diazepam, escitalopram, moclobemide, norclobazam, omeprazole, pantoprazole, sertraline</p>

Mental Health


Cannabis (THC) appear to affect the same reward system as alcohol, cocaine, opioids.

Evidence for cannabis physiological & psychological dependence:

- irritability, anxiety, disturbed sleep, craving

Mental wellness

- Worsen sub-clinical, stable mental illness
- Effects on motivation
- Psychosis in genetically susceptible individuals



Tolerance & Adverse Effects (AEs)

Tolerance

- Mood, sleep
- Psychomotor performance
- Arterial pressure
- Antiemetic properties

Common AEs

- **Anticholinergic effects** (dry mouth, blurry vision, urinary retention, tachycardia, constipation, hypertension).
- **CNS effects** (ataxia, cognitive dysfunction, hallucination).

Cannabis Hyperemesis Syndrome

At The Dispensary: virtual/in-person/www



The “Budtenders” aka “Who’s Behind the Counter”

- 158 budtenders, 56% had received formal training to become a budtender.
- For workplace characteristics, trained budtenders were
 - more likely to report budtender as their primary job (74% vs 53%)
 - practice more than 5 years (34% vs 11%)
 - receive sales commission (57% vs 16%)
 - less likely to perceive medical decision-making as very important (47% vs 68%) & have a patient-centered philosophy (77% vs 89%)
- Budtenders who are formally trained exhibit significantly different patterns of interaction with medical cannabis patients.
 - they were significantly more likely to exchange information with patients through e-mail (58% vs 39%), text message (46% vs 30%), mobile app (33% vs 11%), video call (26% vs 3%) & social media (51% vs 23%).
 - had significantly lower Internet usage

The “Budtenders” aka “Who’s Behind the Counter”

- 55 dispensary staff, 55% reported some formal training, with 20% reporting medical/scientific training.
- 94% indicated that they provide specific cannabis advice.
- Staff trended toward recommendations of Indica for anxiety, chronic pain, insomnia, nightmares & Tourette's syndrome.
- Indica/hybrid plants for post-traumatic stress disorder (PTSD)/trauma and muscle spasms.
- Dispensary staff were most likely to recommend a 1:1 ratio (THC):(CBD) for patients suffering from anxiety, Crohn's disease, hepatitis C, and PTSD/trauma
- Patients seeking appetite stimulation were most likely to be recommended THC.
- High CBD for arthritis and Alzheimer's disease & a high CBD or 1:1 ratio for ALS, epilepsy, and muscle spasms.
- Conclusions: Although many dispensary staff are making recommendations consistent with current evidence, some are recommending cannabis that has either not been shown effective for, or could exacerbate, a patient's condition.
- Findings underscore the importance of consistent, evidence-based, training of dispensary staff who provide specific recommendations for patient medical conditions.


The State of Cannabinoid Testing

Of the thousands of cannabinoid products being sold in the market, only a handful undergo testing for quality, safety, and effectiveness.

This map shows how cannabinoid products are regulated by each state, in comparison to FDA-approved medications.

FDA APPROVAL PROCESS

Valid as of August 25, 2019. Check a state's website for the most up-to-date information.




Source - <https://www.cannabinoidclinical.com/fda-regulation-cannabinoids>

Recommend Only Products that Are Properly Labeled

- Label information should include the ingredients and the milligrams of each cannabinoid per dose.
- Recommend only products from companies that test for potency, pesticides, mold, and bacteria.
- Mindful of byproducts of production (e.g., solvents).

PROFILE			
SOUR DREAM			
GROWN BY MORNING SUN FARMS			
DOSE: 4 second draw on a fully charged CCELL™			
Cannabinoids Per Dose	Doses Per 500mg Cartridge		
3.01 mg	110 draws		
BATCH ID	BEST BY		
S1030175029	10/04/2018		
CULTIVATION DATE	PRODUCTION DATE		
SUMMER 2017	10/04/2017		
CANNABINOIDS	%	Total	per Dose
THC	56.2%	281	2.55
THCa	5%	25	.23
CBD	2.6%	13	.12
CBG	.7%	3.5	.03
CBN	.7%	3.5	.03
CBDa	.6%	3	.03
CBGa	.4%	2	.02
TERPENES	%	Total	per Dose
CARYOPHYLLENE	1.72%	8.6	—
HUMULENE	.87%	4.35	—
LIMONENE	.38%	1.9	—
TERPINOLENE	.23%	1.15	—
MYRCENE	.17%	.85	—
α-PINENE	.13%	.65	—
β-PINENE	.11%	.55	—
BISABOLOL	.10%	.5	—
UNKNOWN	2.77%	13.85	—

Cannabaceutical™ Facts	
Tested On: January 1, 2011	
	YOUR LOGO HERE
Blue Dream	
Sativa Hyb.	
14.20% Wt. Loss on Drying	Safety Screen
Δ ⁹ -THC Max: 13.6 %	Total Aerobic GOLD
Δ ⁹ -THCA 14.9 %	Enterobacteria SILVER
Δ ⁸ -THC 0.53 %	Yeast & Mold BRONZE
CBD Max: 7.60 %	Pesticides PASS
CBDA 8.12 %	Patients can visit
CBD 0.48 %	www.TheWercShop.com
CBN: 0.25 %	to learn more about this label and the test types reported.
<small>Do not use while operating a car or heavy machinery. Keep out of reach of children. For medical use only. % = Wt.%</small>	



Chemical Varieties/”chemovars”



Though cannabis is biologically classified as a single species: *Cannabis Sativa*, there are at least three distinct plant varieties:

- Cannabis Sativa
- Cannabis Indica
- Cannabis Ruderalis

(Pennisi, 2017)

www.leafly.com

www.safeaccessnow.org/using_medical_cannabis

	
Indica	Sativa
Morphology: Short and bushy; suitable for indoor gardens	Morphology: Tall and thin; suitable for outdoor gardens
Geographical Origins: Areas between 30 to 50 degrees latitude.	Geographical Origins: Areas between 0 and 30 degrees latitude
Effects: Tend to be sedating and relaxing with full-body effects	Effects: Tend to be uplifting and creative with cerebrally-focused effects
Symptom Relief: Anxiety, insomnia, pain, muscle spasms	Symptom Relief: Depression, ADD, fatigue, mood disorders

↓THC ↑CBD

↑THC ↓CBD

Practical Dosing

Regardless of the specific physiological system, the effects of cannabis are dependent on many factors:

- Dose, variety
- Route (Inhalation, oral, transmucosal, transdermal, topical)
- Timing
- General health (medical co-morbidities), Age
- Use of other substances/medications
- Chronic user of cannabis versus naive

https://www.colorado.gov/pacific/sites/default/files/MED%20Equivalency_Final%2008102015.pdf

Lack of Standardization Makes Dosing a Challenge for Patients & Practitioners

Overconsumption:

- Re-dosing too soon
- Delayed on-set with oral dosing (>120 minutes)
- Hostile behavior/erratic speech/mild psychosis

The L.E.S.S. Method: A measured approach to oral cannabis dosing

Start Low

- Establish potency
- Go slow
- Supplement as needed

(Erowid & Erowid, 2011)

Oral vs Inhaled

	INHALED	ORALLY INGESTED
Peak Blood Levels (min)	3-10	60-120
Bioavailability (%)	10-40	<15
Time to peak psychoactive activity (min)	20	120-240

Practical Dosing

Average adult dosing of THC:

- Cannabis-naïve individuals 2.5-5 mg
- Daily - weekly users 10-20 mg
- Daily+ 25 mg+

➤ Doses exceeding 20–30 mg/day may increase adverse events or induce tolerance without improving efficacy.


<https://www.leafly.com/news/cannabis-101/cannabis-edibles-dosage-guide-chart>

(MacCallum & Russo, 2018)

■ Average adult dosing of CBD:
300-1500 mg/day

<https://www.webmd.com/vitamins/ai/ingredientmono-1439/cannabidiol>

(MacCallum & Russo, 2018)



Practical Dosing

- Sativex® (1:1 THC/CBD): Spasticity due to multiple sclerosis.

- 2.7mg/2.5mg BID

(max 32.4mg/30mg/day)

<https://www.medicines.org.uk/emc/product/602>

- Epidiolex® (CBD): Seizures (Dravet/Lennox-Gastaut)

- 5 mg/kg oral BID

(max 20 mg/kg/day)

https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf

Cannabidiol (CBD)

Defining Terms:


- CBD from Hemp (↑contaminants, ↓THC)
- CBD from cannabis sativa (↑THC, ↑purity)
- Hemp Oil (seeds of hemp plant, little/no CBD, no THC, +essential fatty acids, +omega three)

Research:

- Epidiolex®
- Other - preliminary research included studies of anxiety, cognition, movement disorders, and pain (anti-inflammatory).
- Efficacy most antidotal (discuss current animal studies).

Safety: Dosing toxicity? Anti-inflammatory effects? CYP450 metabolism.

Side Effects: Fatigue, diarrhea, changes of appetite/weight, dry mouth. Transaminase elevations (reported in Epidiolex studies).



Consumer Brands Association (CBA)



To enhance safety & ensure appropriate regulation of CBD products.

- CBA is NOT a government agency

<https://consumerbrandsassociation.org/>

Grocery Manufacturers Association (GMA): survey of 2,056 U.S. adults (age 18 and older)

<https://progressivegrocer.com/gma-consumers-confused-about-cbd>


- 1:3 of Americans use a CBD product
- 76% assume that CBD products are subject to federal regulations and safety oversight
- 66% believe CBD is safe
- >50% pain, anxiety, sleep
- 39% believe that CBD is just another name for marijuana

Who Uses CBD?




of Americans have tried CBD at least once in the past two years.


How Old They Are



What Do People Use CBD For?



How CBD Use Differs by Age



Practical Discussion in the Office

- Patient provider treatment agreement (if for medicinal use).
<https://adai.uw.edu/mcacp/docs/treatmentagreement.pdf>
- Requirement of patient obtaining a state issued medical cannabis card.
- Documentation of counseling if recreational use discussion.
- It is not illegal to have a discussion and provide counseling.
- Having the discussion, does not mean your endorsement or condoning of behavior.
- Provide resources

The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients via a Written Document (Wilseya, et al., 2015)

- Obligation to understand and inform patients on key issues of the evidence base on cannabinoid therapeutics.
- One way to fulfill this obligation might be to use of a written agreement to describe & minimize risks.
- Method of educating patients in a manner analogous to other treatment agreements.

Final Takeaways

- Familiarize yourself with
 - THC, CBD dosing
 - drug : drug (plant) interactions, side effects, withdrawal
 - local dispensaries & counsel patient to accordingly
- **Consider The Treatment Agreement**
- Continue to remember “marijuana” is Federally illegal
- Informed about state laws
- Mindful of addiction, abuse, mental health issues

Thank You



Tmallick@stanfordhealthcare.org

 @tmallic

 <https://www.linkedin.com/in/theresa-mallick-searle>

Resources

Dispensary Information: Patient Focused Certification

<http://patientfocusedcertification.org/certification/>

- Addresses product & distribution safety.
- Based on quality standards for medical cannabis products and businesses issued by the American Herbal Products Association (AHPA) and the American Herbal Pharmacopoeia (AHP) Cannabis monograph.

<http://camcd-acdcm.ca/>

- More and more states are mandating certification and regulated licensures from dispensaries (e.g. FL).

Resources

Canadian Consortium for the Investigation of Cannabinoids (CCIC): www.ccic.net

- Accredited cannabinoid education (ACE) programs
- Informed by needs assessments, expert faculty

- International Cannabinoid Research Society (ICRS): <https://icrs.co/>
- International Association for Cannabinoid Medicine (IACM): www.cannabis-med.org
- University of Washington & Alcohol and Drug Abuse Institute (ADAI)
- <http://adai.uw.edu/mcacp/index.htm>
- Society of Cannabis Clinicians: www.cannabisclinicians.org
- <https://www.cannabinoidclinical.com/cannabinoid-resource> (site sponsored by Greenwich Biosciences, Inc.)

Resources

<https://www.ukmccs.org/wp-content/uploads/2020/06/A-Clinicians-Guide-to-CBD-v1-June-2020.pdf>



TABLE OF CONTENTS

01	Introduction	11	Discussing CBD with patients
02	The Endocannabinoid System	12	Drug interactions
03	What is CBD?	14	Side effects
06	Key differences between Hemp, CBD and cannabis oils	16	Legalities of CBD products in the UK
07	Indicated uses of CBD	18	What should consumers look for in CBD products?
08	In what forms do patients consume CBD?	19	Checklist for CBD products
10	Dosing CBD	20	References

Resources

Cannabis & CBD Guide - Consumer Reports

Your Guide to CBD



A Guide to CBD and Cannabis for Older Adults



Is It Safe to Vape CBD?



CBD Goes Mainstream



How to Shop for CBD



How to Safely Use CBD: Should You Inhale, Spray, Apply, or Eat It?



CBD May Be Legal, But Is It Safe?

Selected References

1. Aggarwal SK et al. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clin J Pain*. 2013. Feb;29(2):162-71.
2. Alsherbiny MA & Li CG. Medicinal Cannabis—Potential Drug Interactions. *Medicines (Basel)*. 2019 Mar; 6(1): 3.
3. Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: An update on current evidence and cannabis science. *Headache Currents*. July/August 2018: 1139-1158.
4. Bergamaschi MM, Queiroz RHC, Zuardi AW, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. *Current drug safety*. 2011;6:237-249.
5. Blake DR et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)* 2006;45:50–2.
6. Bonnet U & Preuss UW. The cannabis withdrawal syndrome: current insights. *Subst Abuse Rehabil*. 2017 Apr 27;8:9-37.
7. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. *Bioorg Med Chem*. 2015;23(7):1377-85.
8. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*. 2014;55(6): 791–802.
9. Erowid E, Erowid F. "The L.E.S.S. Method: A Measured Approach to Oral Cannabis." *Erowid Extracts* Nov 2011;21:6-9.
10. Fine PG et al. The endocannabinoid system, cannabinoids, and pain. *Rambam Maimonides Med J*. 2013 Oct 29;4(4):e0022.
11. Guindon J & Hohmann A. The endocannabinoid system and pain. *CNS Neurol Disord Drug Targets* 2009;8:403-421.
12. Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and Practices of Cannabis Dispensary Staff. *Cannabis Cannabinoid Res*. 2016 Dec 1;1(1):244-251.
13. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *JAMA*. 2015 Jun 23-30;313(24):2474-83.
14. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *British Journal of Pharmacology*. 2015;172(20):4790-4805.

Selected References

15. MacCallum CA, Lo LA, Boivin M. "Is medical cannabis safe for my patients?" A practical review of cannabis safety considerations. *Eur J Intern Med*. 2021 Jul;89:10-18.
16. MacCallum CA & Russo EB. Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine* 2018;49:12–19.
17. Martin-Sanchez E et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Med*. 2009Nov;10(8):1353-68.
18. Moulin D et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. *Pain Res Manag*. 2014 Nov-Dec; 19(6):328-35.
19. Nugent S, Morasco B, O'Neil M, et al. The effects of cannabis among adults with chronic pain and an overview of general harms. *Annals of Internal Medicine* 2017;167(5):319-332.
20. Olfson M, Wall MM, Liu SM, Blanco C. Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States. *Am J Psychiatry*. 2018 Jan 1;175(1):47-53. doi: 10.1176/appi.ajp.2017.17040413.
21. Peiper NC, Gourdet C, Meinhofer A, Reiman A, Reggente N. Medical Decision-Making Processes and Online Behaviors Among Cannabis Dispensary Staff. *Subst Abuse*. 2017 Aug 21;11:1178221817725515.
22. Pennisi E. A new neglected crop: cannabis. *Science*. 2017;356(6335):232-233.
23. Rani Sagar D, Burston JJ, Woodhams SG, Chapman V. Dynamic changes to the endocannabinoid system in models of chronic pain. *Philos Trans R Soc Lond B Biol Sci*. 2012 Dec 5;367(1607):3300-11.
24. Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. *Pharmacotherapy*. 2016 May;36(5):505-10.

Selected References

25. Russo E. Cannabinoids in the management of difficult to treat pain. *Ther Clin Risk Manag* 2008;4(1):245-259.
26. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. *Cannabis and Cannabinoid Research* 2016 1(1):154-165.
27. Russo EB. Cannabidiol Claims and Misconceptions. *Trends Pharmacol Sci*. 2017 May;38(5):499.
28. Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. *J Med Toxicol*. 2017, 13(1):71-87.
29. Stout SM & Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. *Drug Metab Rev*. 2014 Feb;46(1):86-95.
30. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. *Ther Drug Monit*. 2004 Apr;26(2):200-5.
31. Wallace E., Andrews S., Garmany C., Jelley M. Cannabinoid Hyperemesis Syndrome: Literature Review and Proposed Diagnosis and Treatment Algorithm. *Southern Medical Journal*. 104(9):659-664, September 2011.
32. Walsh Z, Gonzalez R, Crosby K, et al. Medical cannabis and mental health: a guided systematic review. *Clin Psychol Rev* 2017;51:15-29.
33. Wilsey B, Atkinson JH, Marcotted TD, Grant I. The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients via a Written Document. *Clin J Pain*. 2015; 31(12): 1087–1096. doi:10.1097/AJP.000000000000145.